Abstract: A compound having a structure as shown in general formula (I), a deuterated compound, a stereoisomer, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and use thereof. The compound has a good PIM kinase inhibitory effect, is a novel and ideal PIM inhibitor having high activity and low toxicity, and can be used for treating and/or preventing hematoma such as acute myeloid leukemia, bone marrow fibrosis and chronic lymphocytic leukemia, solid tumors such as gastric cancer and prostate cancer, and other diseases.

Abstract: The invention relates to an indole derivative shown in general formula (I-1) and its use in preparing drugs for preventing and/or treating indications of S1P receptor related disorders. The indole derivative of the invention is replaced by R1, R2, R5, and R6 at different sites respectively, and the obtained modified indole derivative has excellent biological activity and is an ideal S1P receptor regulator with high efficiency. Compounds of general formula (I-1) can be used to treat and/or prevent Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, multiple sclerosis, atopic dermatitis, eosinophilic esophagitis, alopecia areata, primary cholangitis, pyoderma gangrenosum, graft-versus-host disease, amyotrophic lateral sclerosis, systemic lupus erythematosus, type I diabetes arteriosclerosis, atherosclerosis, scleroderma, autoimmune hepatitis, acne, microbial infection, viral infection, and other autoimmune and inflammatory diseases.

Abstract: A data retention time calculation method, apparatus, and device. said method includes: acquiring a temperature value of a solid state disk(SSD) in a past preset duration; according to the temperature value and a preset temperature acceleration model, calculating an acceleration factor corresponding to the temperature value; taking a product of the preset duration and the acceleration factor as a life cycle increment in the past preset duration; and adding the life cycle increment to a retention time of target data, so as to update a storage area of the target data in view of a preset life cycle.

Abstract: Bruton's tyrosine kinase (BTK) inhibitors have the following Formula (I) or (II):

Abstract: Devices, methods, systems, and computer-readable media for a dynamic temperature sensor are described herein. One or more embodiments include a device, comprising: a controller that includes a variable voltage output coupled to a sensor, wherein the controller provides a voltage segment to the sensor based on a signal of the sensor received at the controller.

Abstract: The present invention relates to a pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and/or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative of the invention is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like.

Abstract: An ultraviolet (UV) light absorption sensing system (100) includes a UV light source (110) configured to provide a UV sample beam (115) of light toward a still or flowing fluid sample (117) along a central axis (118) of a test cell (120), wherein the central axis (118) is substantially orthogonal to a direction of fluid flow. A reference light source (130) is configured to provide a reference beam (133) along the central axis (118) of the test cell (120). A first detector (140) is positioned to detect a first portion (128) of the UV sample beam (115) and a first portion (138) of the reference beam (133) that traverse the test cell (120). A second detector (142) is positioned to detect a second portion (146) of the UV sample beam (115) and a second portion (148) of the reference beam (133) directly from the UV light source (110) and reference light source (130).

Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.

Abstract: Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.

Abstract: An ultraviolet (UV) light absorption sensing system (100) includes a UV light source (110) configured to provide a UV sample beam (115) of light toward a still or flowing fluid sample (117) along a central axis (118) of a test cell (120), wherein the central axis (118) is substantially orthogonal to a direction of fluid flow. A reference light source (130) is configured to provide a reference beam (133) along the central axis (118) of the test cell (120). A first detector (140) is positioned to detect a first portion (128) of the UV sample beam (115) and a first portion (138) of the reference beam (133) that traverse the test cell (120). A second detector (142) is positioned to detect a second portion (146) of the UV sample beam (115) and a second portion (148) of the reference beam (133) directly from the UV light source (110) and reference light source (130).

Abstract: Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.

Abstract: A pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase (Janus kinase) inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and/or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like.

Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.

Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.

Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.